FDA clears targeted cholangiocarcinoma therapy
-
By
-
Kathryn Wighton
-
September 24, 2026
-
2 min
By
Kathryn Wighton
September 24, 2026
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.
September 8, 2026
In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.
September 8, 2026